Clinical and biological features of DS-ALL
| Biological features | • Almost exclusively B cell precursor immunophenotype • Heterogeneity - no DS ALL typical genetic abnormality as in DS myeloid leukemias • Decreased prevalence of favorable chromosomal aberrations of childhood ALL (ETV6-RUNX1, high hyperdiploid) • Decreased prevalence of unfavorable chromosomal aberrations of childhood ALL (BCR-ABL, AF4-MLL) • Aberrant expression of CRLF2 in 60% of DS-ALLs • Large proportion of cytogenetically normal ALL |
| Clinical features | • No Infant leukemia • High risk of relapse • High infectious associated therapy related mortality throughout treatment period |
| Biological features | • Almost exclusively B cell precursor immunophenotype • Heterogeneity - no DS ALL typical genetic abnormality as in DS myeloid leukemias • Decreased prevalence of favorable chromosomal aberrations of childhood ALL (ETV6-RUNX1, high hyperdiploid) • Decreased prevalence of unfavorable chromosomal aberrations of childhood ALL (BCR-ABL, AF4-MLL) • Aberrant expression of CRLF2 in 60% of DS-ALLs • Large proportion of cytogenetically normal ALL |
| Clinical features | • No Infant leukemia • High risk of relapse • High infectious associated therapy related mortality throughout treatment period |